Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a report released on Monday, MarketBeat Ratings reports. They currently have a $540.00 price target on the biopharmaceutical company’s stock. Guggenheim’s price target suggests a potential upside of 24.78% from the stock’s current price.

REGN has been the topic of several other reports. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target on the stock. in a report on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. Finally, Canaccord Genuity set a $522.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 28th. Four research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $489.73.

Shares of Regeneron Pharmaceuticals (REGN) traded down 0.88% during trading on Monday, reaching $428.95. The company had a trading volume of 368,729 shares. The stock has a market capitalization of $45.48 billion, a price-to-earnings ratio of 43.03 and a beta of 1.63. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The company’s 50 day moving average is $449.04 and its 200-day moving average is $458.26.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period in the prior year, the company earned $2.82 earnings per share. The firm’s revenue was up 21.2% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post $14.94 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Reaffirmed by Guggenheim” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/23/regeneron-pharmaceuticals-inc-regn-receives-new-coverage-from-analysts-at-guggenheim.html.

In other news, CFO Robert E. Landry sold 189 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Sanofi purchased 166,415 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. In the last quarter, insiders sold 89,468 shares of company stock valued at $42,312,448. 10.80% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. FMR LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. grew its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after buying an additional 41,406 shares during the period. Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after buying an additional 148,962 shares during the period. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 4.3% in the 1st quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after buying an additional 29,252 shares during the period. 67.42% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.